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Amyloid deposits, constituted of amyloid beta (Aβ) aggregates, are a characteristic feature
of several neurodegenerative diseases, such as Alzheimer’s, mild cognitive impairment
and Parkinson’s disease. They also have been recently implicated in the pathogenesis of
retinal damage, as well as age-related macular degeneration and glaucoma. Glaucoma is
a progressive optic neuropathy characterized by gradual degeneration of neuronal tissue
due to retinal ganglion cell loss, associated to visual field loss over time resulting in
irreversible blindness. Accumulation of Aβ characterizes glaucoma as a protein misfolding
disease, suggesting a pathogenic role for oxidative stress in the pathogenesis of retinal
degenerative damage associated to glaucoma. There is a growing body of evidence
demonstrating a link between Alzheimer’s disease and glaucoma. Further, several heat
shock proteins (HSPs) members have been implicated both in neurodegenerative diseases
and glaucomatous apoptosis. To maintain redox homeostasis vitagenes, as integrated
mechanisms, operate actively to preserve cell survival under condition of stress. Vitagenes
encode for sirtuin, thioredoxin and HSPs. The present study was designed to investigate
cellular stress response mechanisms in the blood of patients with glaucoma, compared
to control subjects. Levels of vitagenes HSP-72, heme oxygenase-1, as well as F2-
isoprostanes were significantly higher in the blood of patients with glaucoma than in
controls. Furthermore, in the same experimental group increased expression of Trx and
sirtuin 1 were measured. Our results sustain the importance of redox homeostasis
disruption in the pathogenesis of glaucoma and highlights the opportunity that new
therapies that prevents neurodegeneration through non-immunomodulatory mechanisms
might be synergistically associated with current glaucoma therapies, thus unraveling
important targets for novel cytoprotective strategies.
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INTRODUCTION
Glaucoma is a progressive optic neuropathy characterized by
degeneration of neuronal tissue due to loss of retinal ganglion
cells (RGCs), with accompanying compromission of visual field
over time (Gupta et al., 2006; Quigley and Broman, 2006). It is
a leading cause of irreversible blindness estimated to affect 79.6
million people worldwide by 2020 (Hinton et al., 1986; Yoneda
et al., 2005). Research studies have demonstrated that RGC dam-
age in glaucoma is not limited to the primary insulted neurons, but
also involves neighboring neurons. The increase in the prevalence
of glaucoma with age is not accounted for only by the increase
in ocular hypertension alone, being accompanied by an increase
in the vulnerability of the optic nerve to the effects of glaucoma
risk factors which increase as function of age. In particular, fac-
tors such as tissue hypoxia, disturbed protein metabolism and
oxidative stress have been identified to interact in a vicious cycle
underlying the pathogenesis of glaucoma (Calandrella et al., 2007;
Gupta et al., 2008), ultimately leading to apoptotic retina gan-
glion cell death (Tatton et al., 2001; Soti et al., 2005; De la Monte
and Wands, 2006). In view of these considerations glaucoma
can be viewed as a neurodegenerative disease which, similarly
to other neurodegenerative pathologies, i.e., Alzheimer’s and
Parkinson’s disease, where irreversible functional deficit ensues
as consequence of neuronal dysfunction and death. There is now
a growing body of evidence demonstrating a link between AD and
glaucoma.
Amyloid deposits, consisting of Aβ, which are a charac-
teristic feature of several neurodegenerative diseases such as
Alzheimer’s (AD), mild cognitive impairment, and Parkinson’s
disease (Hinton et al., 1986) have been recently implicated in the
pathogenesis of retinal damage, macular degeneration, and glau-
coma (Yoneda et al., 2005). Accordingly, drugs designated to target
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β-amyloid (Aβ) has been found to reduce apoptotic degenera-
tion of RGCs, as observed in vitro and in vivo. Furthermore, the
presence of increased levels of Aβ characterizes glaucoma as a
protein misfolding disease, also suggesting a role for oxidative
stress in the pathogenesis of retinal degenerative damage associ-
ated to glaucome. Although oxidative stress has been recognized
to play a critical role in the development and progression of
glaucoma, yet, the exact mechanisms remain elusive. Oxidative
stress can cause oxidative attack to DNA, proteins, and lipids,
leading to DNA and protein modification, thus sustaining the
pathophysiology of degenerative damage of RGCs (Gupta et al.,
2006). Relevant to protein misfolding, of emerging interest are
heat shock proteins (HSPs), specialized molecular chaperones
which mediate various cellular functions. HSPs are up regulated
in response to conditions of stress in order to restore normal cell
integrity (Soti et al., 2005). The heat shock response, an impor-
tant component of vitagene family, contributes to establishing a
cytoprotective state in a wide variety of human diseases. Vita-
genes include, besides HSPs 70 and 32, the latter also called heme
oxygenase-1 (HO-1), thioredoxin and sirtuins (Butterfield et al.,
2010, 2011). Several families of HSP have been implicated in neu-
rodegenerative diseases and glaucomatous RGC apoptosis with
increased levels of circulating autoantibodies to alpha-crystallins
and HSP-27 and increased immunostaining of HSP-60, HSP-27 in
RGCs and the retinal blood vessels in glaucoma patients (Shieds
et al., 1996; Izzotti et al., 2006). In a rat glaucoma model, treat-
ment with geranylgeranylacetone increases HSP-72 synthesis while
reducing markedly RGC loss, possibly through interactions with
different protein kinases, such as Akt kinase, and the inhibition
of NF-kB. In this study we tested the hypothesis that there may
be a causal relationship between AD and glaucoma that may
be explained by systemic oxidative stress and dysregulation of
cellular stress response. Present work elucidated cellular stress
response in peripheral cells in patients with glaucoma as com-
pared to healthy volunteers, as control, in order to gain insight
into the pathogenic mechanisms operating in the neurodegener-
ative damage associated with this disease and exploit the possible
role of vitagenes in opening up new therapeutic targets for limit-




Eighteen patients (12 males and six females, mean age
60 ± 15 years) with diagnosis of hypertensive primary open-
angle glaucoma (POAG), with typical optic nerve head and
visual field damage, were included in the study. Mean MD
and PSD were respectively −7.5 ± 8.6 dB, and 4.2 ± 3.8 dB.
Twenty age-matched healthy volunteers were recruited as con-
trols. Patients and control subjects underwent IOP measure-
ment by Goldmann applanation tonometer, optic nerve head
examination by 78 D lens at the slit lamp, and visual field
test 24-2 SITA standard, by a 750 Humprey perimeter (HFA
II). Clinical characteristics of patients and control subjects are
shown in Table 1. Patients with normal tension glaucoma,
previous uveitis, diabetes, arterial hypertension were excluded.
The study was conducted according to guidelines of local
Ethics Committee, and informed consent was obtained from all
patients.
SAMPLING AND LYMPHOCYTE PURIFICATION
Blood (5 ml) collected from controls and patients into tubes
containing EDTA, was divided into two aliquots, 1 and 4 ml
respectively. One aliquots (1 ml) was centrifuged at 3000 × g for
10 min at 4◦C to separate serum from red blood cells, while 4 ml
aliquots, were utilized for lymphocytes purification, which was
accomplished by using the Ficoll Paque System following the pro-
cedure provided by the manufacturer (GE Healthcare, Piscataway,
NJ, USA).
WESTERN BLOT ANALYSIS
HSP-70, HO-1, Trx, and Sirt-1 protein levels were estimated
by Western blot analysis which was accomplished as previously
described in Calabrese et al. (2012). Plasma samples were pro-
cessed as such, while the isolated lymphocyte pellet was homoge-
nized and centrifuged at 10,000 × g for 10 min. The supernatant
was then used for analysis after determination of protein con-
tent. Proteins extracted for each sample, at equal concentration
(40 μg), were boiled for 3 min in sample buffer (containing 40 mM
Tris-HCl pH 7.4, 2.5% SDS, 5% 2-mercaptoethanol, 5% glycerol,
0.025 mg/ml of bromophenol blue) and then separated on a poly-
acrylamide mini gels precasting 4–20% (cod NB10420 NuSept Ltd
Australia). Separated proteins were transferred onto nitrocellulose
membrane (BIO-RAD, Hercules, CA, USA) in transfer buffer con-
taining (0.05% di SDS, 25 mM di Tris, 192 mM glycine and 20%
v/v methanol). The transfer of the proteins on the nitrocellulose
membrane was confirmed by staining with Ponceau Red which
was then removed by three washes in PBS (phosphate buffered
saline) for 5 min each. Membranes were then incubated for 1 h
at room temperature in 20 mM Tris pH 7.4, 150 mM NaCl and
Tween 20 (TBS-T) containing 2% milk powder and incubated
with appropriate primary antibodies, namely anti-HSP-70, anti-
HO-1, anti-Trx and anti Sirt-1 polyclonal antibody (Santa Cruz
Biotech. Inc.), overnight at 4◦C in TBS-T. The same membrane
was incubated with a goat polyclonal antibody anti-beta-actin (SC
1615 Santa Cruz Biotech. Inc., Santa Cruz, CA, USA, dilution
1:1000) to verify that the concentration of protein loaded in the
gel was the same in each sample. Excess unbound antibodies were
removed by three washes are with TBS-T for 5 min. After incu-
bation with primary antibody, the membranes were washed three
times for 5 min. in TBS-T and then incubated for 1 h at room
temperature with the secondary polyclonal antibody conjugated
with horseradish peroxidase (dilution 1:500). The membranes
were then washed three times with TBS-T for 5 min. Finally, the
membranes were incubated for 3 min with SuperSignal chemilu-
miniscence detection system kit (Cod 34080 Pierce Chemical Co,
Rockford, IL, USA) to display the specific protein bands for each
antibody. The immunoreactive bands were quantified by captur-
ing the luminescence signal emitted from the membranes with the
Gel Logic 2200 PRO (Bioscience) and analyzed with Molecular
Imaging software for the complete analysis of regions of interest
for measuring expression ratios. The molecular weight of proteins
analyzed was determined using a standard curve prepared with
protein molecular weight.
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Table 1 | Clinical data of glaucoma patients and control subjects.
Number of subjects Age (Mean ± SD) Gender (F/M) md (Mean ± SD) Psd (Mean ± SD)
Patients 18 60 ± 15 7/1 −7.5 ± 8.6 4.2 ± 3.8
Controls 20 73 ± 5 2/8 −1.2 ± 1.1 0.8 ± 0.3
Md, mean defect; psd, pattern standard deviation.
MEASUREMENT OF F2-ISOPROSTANES
F2-isoprostanes were determined by HPLC according to the pro-
cedure of Ritov et al. (2002). F2-isoprostane content in plasma was
expressed in nM.
DETERMINATION OF PROTEIN
Protein concentration in all experimental samples was determined
by the bicinchoninic acid protein assay (Pierce, Rockford, IL, USA)
according to Smith et al. (1985) and using serum bovine albumin
as standard.
STATISTICAL ANALYSIS
Results were expressed as means ± S.E.M. Each experiment was
performed, unless otherwise specified, in triplicate. Data were ana-
lyzed by one-way ANOVA, followed by inspection of all differences
by Duncan’s new multiple-range test. Differences were considered
significant at P < 0.05.
RESULTS
In our study we evaluated the expression of stress proteins in
plasma and lymphocytes of glaucomatous patients compared to
controls. Among the 70 kDa family of HSPs we evaluated the
inducible HSP-70 (HSP-72) isoform and its expression. As shown
in Figure 1A, a significant (P < 0.05) increase in HSP-70 was
found in lymphocytes of patients with glaucoma with respect to
healthy control subjects. A representative immunoblot is reported
in Figure 1B. Western blot analysis of plasma probed for HSP-70
are reported in Figure 2A, which shows that HSP-70 expres-
sion increased significantly (P < 0.05) in patients with glaucoma,
compared to controls. A representative immunoblot is shown in
Figure 2B.
Heme oxygenase-1, another HSP-32 endowed with cytoprotec-
tive properties (Soti et al., 2005), was found expressed at signifi-
cantly higher levels in lymphocytes of patients with glaucoma than
in controls (Figure 3A). A representative immunoblot is illustrated
in Figure 3B. Similarly to lymphocyte finding, patients with glau-
coma exhibited higher level plasma HO-1 protein then healthy
controls (Figures 4A,B).
Analysis of lymphocytes in patients with glaucoma, compared
to control group, revealed a significant (P < 0.05) increase of
Trx expression (Figure 5A), while in the plasma there was no
statistically significant difference between the two experimental
groups (Figure 6A). Representative immunoblots are reported in
Figures 5B and 6B, respectively.
Interestingly, we found significantly (P < 0.05) higher levels
of sirtuin-1 in lymphocytes of patients with glaucoma than in the
control group (Figure 7A). Consistent with the changes found
in lymphocytes, analysis of plasma confirmed increased protein
FIGURE 1 | (A) HSP-70 protein levels in plasma of glaucoma and control
subjects. Samples from control and glaucoma patients were assayed for
HSP-70 expression by Western blot. A representativ eimmunoblot is
shown. β-actin has been used as loading control. (B) Densitometric
evaluation: the bar graph shows the values are expressed as mean
standard error of mean of 3 independent analyses. *P < 0.05 vs. control.
D.U., densitometric units; CTRL, control.
levels of sirtuin-1, higher in patients with glaucoma as to com-
pare with the healthy control group (Figure 8A). Representative
immunoblots are shown in Figures 7B and 8B, respectively. As
to our knowledge this is the first evidence of changes in sirtuin-1
expression in glucomatous pathology, although this finding may
not be a marker specific for this progressive chronic inflammatory
systemic disease.
Further, we evaluated systemic pro-oxidant conditions, by
measuring lipid-derived circulating F2 isoprostanes. We found
a significant increase (P < 0.05) of total F2-isoprostanes in the
plasma of patients with glaucoma (P < 0.05) with respect to
controls (Figure 9).
DISCUSSION
Glaucoma is one of the leading causes of vision loss worldwide.
Open-angle glaucoma, the most common form of glaucoma,
is characterized by a progressive loss of RGCs and atrophy of
the optic nerve, resulting in loss of visual field (Hinton et al.,
1986; Yoneda et al., 2005). Several theories have been pro-
posed, including mechanical and vascular pathogenesis for the
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FIGURE 2 | (A) HSP-70 protein levels in lymphocytes of glaucoma and
control subjects. Samples from controls and glaucoma patients were
assayed for HSP-70 expression by Western blot. A representative
immunoblot is shown. β-actin has been used as loading control.
(B) Densitometric evaluation: the bar graph shows the values are
expressed as mean standard error of mean of 3 independent analyses.
*P < 0.05 vs. control. D.U., densitometric units; CTRL, control.
FIGURE 3 | (A) HO-1 protein levels in plasma of glaucoma and control
subjects. Samples from control and patients with glaucoma were assayed
for HO-1 expression by Western blot. A representative immunoblot is
shown. β-actin has been used as loading control. (B) Densitometric
evaluation: the bar graph shows the values are expressed as mean
standard error of mean of 3 independent analyses. *P < 0.05 vs. control.
D.U., densitometric units; CTRL, control.
FIGURE 4 | (A) HO-1 protein levels in lymphocytes of glaucoma and control
subjects. Samples from control and patients with glaucoma were assayed
for HO-1 expression by Western blot. A representative immunoblot is
shown. β-actin has been used as loading control. (B) Densitometric
evaluation: the bar graph shows the values are expressed as mean
standard error of mean of 3 independent analyses. *P < 0.05 vs. control.
D.U., densitometric units; CTRL, control.
FIGURE 5 | (A) Sirtuin-1 protein levels in plasma of glaucoma and control
subjects. Samples from control and patients with glaucoma were assayed
for Sirt-1 expression by Western blot. A representative immunoblot is
shown. β-actin has been used as loading control. (B) Densitometric
evaluation: the bar graph shows the values are expressed as mean
standard error of mean of three independent analyses. *P < 0.05 vs.
control. D.U., densitometric units; CTRL, control.
glaucomatous optic neuropathy. Elevated intraocular pressure is
a strong risk factor, but a subset of glaucoma patients has nor-
mal intraocular pressure designating a normal tension glaucoma.
Clearly, other factors different from intraocular pressure, such
as genetic factors, are thought to be involved in RGC apoptotic
cell death in glaucoma. The e4 allele of the APOE gene has been
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FIGURE 6 | (A) Sirtuin-1 protein levels in lymphocytes of glaucoma and
control subjects. Samples from control and patients with glaucoma were
assayed for Sirt-1 expression by Western blot. A representative immunoblot
is shown. β-actin has been used as loading control. (B) Densitometric
evaluation: the bar graph shows the values are expressed as mean
standard error of mean of 3 independent analyses. *P < 0.05 vs. control.
D.U., densitometric units; CTRL, control.
FIGURE 7 | (A) Thioredoxin protein levels in plasma of glaucoma and
control subjects. Samples from control and patients with glaucoma were
assayed for Trx expression by Western blot. A representative immunoblot is
shown. β-actin has been used as loading control. (B) Densitometric
evaluation: the bar graph shows the values are expressed as mean
standard error of mean of 3 independent analyses. P < 0.05 vs. control.
D.U., densitometric units; CTRL, control.
FIGURE 8 | (A) Thioredoxin protein levels in lymphocytes of glaucoma and
control subjects. Samples from control and patients with glaucoma were
assayed for Trx expression by Western blot. A representative immunoblot is
shown. β-actin has been used as loading control. (B) Densitometric
evaluation: the bar graph shows the values are expressed as mean
standard error of mean of 3 independent analyses. *P < 0.05 vs. control.
D.U., densitometric units; CTRL, control.
FIGURE 9 |Total F2-isoprostanes levels in plasma glaucoma patients.
Plasma samples from patients with glaucoma and age-matched controls
were assayed for total F2-isoprostanes. Data are expressed as
mean ± SEM of 18 to 20 patients per group. *P < 0.05 vs. controls.
also considered in the pathophysiology of open-angle glaucoma,
although the question still remains elusive (Quigley and Broman,
2006).
Oxidative stress is considered an important risk factor for the
development of primary angle-closure glaucoma and increased
levels of oxidative stress products have been documented in pri-
mary angle-closure glaucoma (Shieds et al., 1996; Izzotti et al.,
2006; Butterfield et al., 2011). Visual loss which often starts in
the periphery and advances involving central vision, has devas-
tating consequences to patient’s quality of life (Gupta et al., 2006;
Quigley and Broman, 2006).
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We have recently demonstrated that increased oxidative stress
and cellular stress response are a systemic presentation of the
oxidative burden occurring in AD patients, rising the conceiv-
able possibility that Alzheimer’s disease might not be exclusively
a primary neurological pathology rather being a systemic oxi-
dant disorder (Siciliano et al., 2011; Cornelius et al., 2013). In
this study we hypothesize that there may be a causal relation-
ship between AD and glaucoma that may be explained by systemic
oxidative stress and dysregulation of cellular stress response. We
have found in patients with glaucoma a systemic condition of
oxidative stress as revealed by upregulation of lipid-derived F2
isoprostanes. This marker of oxidative stress was found in the
blood of patients with glaucoma at significantly higher levels
than in controls. Similarly to other oxidant disorders, such as
AD (Calabrese et al., 2012; Mayeux and Stern, 2012) or multiple
sclerosis (Calabrese et al., 2010b) a direct relationship, although
not necessarily causal, may exist between organ specific pathol-
ogy and systemic alterations underlying or reflecting the local
oxidative status (Ferreira et al., 2004). Reactive oxygen species
(ROS) are an essential component of intracellular signaling net-
work, regulated through the intrinsic antioxidant capacity of a
cell, but when ROS formation exceedingly increases damage to
DNA, proteins, and lipids macromolecules ensues. During cel-
lular metabolism mitochondrial compartment accounts for the
major source of ROS generation. However, excess in free rad-
ical production induces oxidative stress and damage. Growing
evidence now sustains a critical role for free radical-induced
oxidative damage in glaucomatous neurodegeneration occur-
ring in different subcellular compartments of RGCs. Consistent
with this notion, oxidatively modified proteins and advanced
glycation end products accumulate in glaucomatous neurode-
generation, thus increasing neuronal susceptibility to glial dys-
function (Shieds et al., 1996; Sloane et al., 2002; Tamura et al.,
2006). This last event, in turn, contributes to propagate neu-
ronal damage resulting in secondary degenerative damage. Fur-
thermore, free radical-mediated oxidative insult in glaucoma
enhances antigen presenting activity of glial cells and hence
stimulates immune response (Tezel, 2006; Calandrella et al.,
2007).
Oxidative damage is one of the most important causes of
brain protein damage and dysfunction in several age-related neu-
rodegenerative disorders including Alzheimer’s disease (Sloane
et al., 2002). RGCs and the optic nerve have demonstrated
similar mechanisms of cell death in glaucoma to those of
Alzheimer’s disease, marking glaucoma as a neurodegenerative
disease (Guo et al., 2006; Pennisi et al., 2011). AD is a progres-
sive neurodegenerative disorder characterized by cognitive and
memory deterioration, as well as changes in personality, behav-
ioral disturbances and an impaired ability to perform activities
of daily living (McKinnon, 2003; Wostyn et al., 2009; Sicil-
iano et al., 2011). AD is known to be the most common form
of dementia and is a major public health problem through-
out the world (Calabrese et al., 2012). In addition to synaptic
degradation and extensive neuronal cell loss, neuropatholog-
ical characteristics of AD include extracellular senile plaques
containing β-amyloid (Aβ) derived from β-amyloid precur-
sor protein (APP) after sequential cleavage by b-secretase and
c-secretase, and intracellular neurofibrillary tangles caused by
abnormally phosphorylated tau protein (De la Monte and Wands,
2006).
There is a growing body of evidence demonstrating a link
between AD and glaucoma. However, the nature of this link
remains obscure. Interestingly, recently published research may
provide a clue toward a better understanding of the high rate of
comorbidity reported between AD and glaucoma.
It is intriguing to note that AD and glaucoma have many
common features. Both are slow and chronic neurodegenerative
disorders with a strong age-related incidence. Studies consistently
report decreased levels of β-amyloid and increased levels of tau in
cerebrospinal fluid from AD patients in comparison with healthy
subjects. Similarly, decreased levels of β-amyloid and significantly
increased levels of tau have been detected in the vitreous fluid from
patients with glaucoma or diabetic retinopathy in comparison with
the levels in a control group (Calabrese et al., 2010b; Pennisi et al.,
2011; Siciliano et al., 2011; Cornelius et al., 2013). This finding
corroborates a role for β-amyloid and tau in the pathogenesis of
glaucoma, suggesting that the neurodegenerative process in these
ocular diseases might share, at least in part, a common mecha-
nism with AD. It was also demonstrated recently that abnormal
tau AT8 is present in human glaucomas with uncontrolled elevated
intraocular pressure. Furthermore, there is evidence of a build-up
of Aβ in RGCs in experimental rat glaucoma. Activation of cas-
pases and abnormal APP processing, which includes production
of Aβ are important events in AD (Bullock and Hammond, 2003;
Guo et al., 2006).
To gain further insight into the role of oxidant/antioxidant
balance in the pathogenesis of glaucoma, in addition to oxida-
tive stress, expression of Sirt-1 and Trx was determined in the
peripheral blood of glaucomatous patients. Interestingly, levels of
vitagenes HSP-72 and HO-1 were significantly higher in the blood
of patients with glaucoma than in controls. These changes were
associated with an increased expression of Trx and sirtuin 1 in the
same experimental group.
To adapt to environmental changes and survive different types
of injuries, as in the case of acute or chronic stress, exposed
cells are continually challenged to activate integrated survival
responses (Bullock and Hammond, 2003). One of these, the heat
shock response actively operate in the optic cell system, under
control of redox regulated gene network, the vitagene network,
recognized to be critical for the intracellular chaperoning func-
tion which is essential for the proper folding of misfolded or
mutated proteins, thereby protecting vulnerable cells from death
(Selkoe, 2001; Rocchi et al., 2003; Guo et al., 2006). As stress
inducible proteins, chaperones help the correct folding and main-
tenance of the proper conformation of essential proteins, thus
promoting cell survival in all those pathological conditions asso-
ciated oxidative stress (Hirota et al., 2002; Calabrese et al., 2010c).
Under oxidative stress conditions, such as that found in patients
with glaucoma, HO-1 was also found increased in lymphocytes
and plasma of patients with glaucoma. HO-1 is an early gene
induced by oxidative stress producing powerful antioxidant and
antinitrosative molecules such as biliverdin and bilirubin (Halli-
well, 2006; Calabrese et al., 2010a, 2013). HO-1 increase in the
lymphocytes of patients with glaucoma may indicate that, in
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response to an oxidant insult, induction of an early gene is a
significant part of the antioxidant response which might have bio-
logical relevance considering the long term course of the disease.
Under stress conditions, induction of sirtuins is a well recog-
nized defense mechanism against oxidative injury, representing
a common feature in a number of neurodegenerative diseases
(Salminen et al., 2008). Here we found that the levels of Sirt-1 in
glaucoma lymphocytes were significantly higher than in controls,
a finding associated with increased content of F2-isoprostanes
as marker of oxidative stress. This is relevant to the pathogen-
esis of glaucoma. Several studies suggest that the Sirt-1 gene is
redox-regulated and its expression appears closely related to con-
ditions of oxidative stress (Drake et al., 2003; Bonda et al., 2011).
Thus, its induction could represent a protective system poten-
tially active against brain oxidative injury (Kessing et al., 2007;
Herranz and Serrano, 2010). In addition, another protein, thiore-
doxin (Trx), which is emerging as critical vitagene involved in
brain stress tolerance was found increased in the same experi-
mental group (Tanaka et al., 2000; Tonissen and Trapani, 2009).
Besides its role in the protection against oxidative stress, Trx is
critically involved in the regulation of cell growth and cell death
(Yi and Luo, 2010; Di Paola et al., 2011). Consistently, modulation
of endogenous cellular defense mechanisms such as the vitagene
network, including HSPs, sirtuin, and thioredoxin proteins may
open a new approaches to therapeutic interventions in diseases
associated with tissue damage and cell death, such as in glau-
comatous neurodegeneration (Dali-Youcef et al., 2007; Dumont
et al., 2009; Ballard et al., 2011). Our data are in favor of the
hypothesis linking oxidative stress to the pathogenesis of glau-
coma, and indicate that stress responsive genes may represent an
important target for novel cytoprotective strategies, as molecules
inducing this defense mechanism, via nutritional and/or pharma-
cological approaches, can exploit the potential for antidegenerative
therapeutic interventions.
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